Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sierra Oncology Inc (SRRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Sierra Oncology Inc 2150 - 885 WEST GEORGIA STREET VANCOUVER A1 V6C 3E8 CAN

https://www.sierraoncology.com P: 604-558-6536

Description:

Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and SRA141. SRA737 is an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key cell cycle checkpoint and central regulator of the DNA Damage Response network. SRA141 is an orally available small molecule inhibitor of cell division cycle 7kinase. Sierra Oncology, Inc., formerly known as ProNAi Therapeutics, Inc., is headquatered in Vancouver, Canada.

Key Statistics

Overview:

Market Capitalization, $K 165,268
Shares Outstanding, K 52,300
Annual Sales, $ 0 K
Annual Net Income, $ -47,867 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -10,000 K
36-Month Beta 2.76
% of Insider Shareholders 5.72%
% of Institutional Shareholders 55.57%

Growth:

1-Year Total Return 115.07%
3-Year Total Return 0.00%
5-Year Total Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 11/09/17
Earnings Per Share ttm -0.95
EPS Growth vs. Prev Qtr 5.00%
EPS Growth vs. Prev Year 62.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

SRRA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -3.73
Price/Earnings to Growth N/A
Return on Equity % -36.93
Return on Assets % -34.96
Net Margin % N/A
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 1.59
Book Value/Share 1.99
Interest Coverage 0.00
Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.